Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

bronchiolitis

  • Home
  • bronchiolitis
Paracetamol vs. Ibuprofen in Infancy: The PIPPA Tamariki Trial Finds No Differential Risk for Eczema or Bronchiolitis
Posted inAllergy & Immunology news Pediatrics

Paracetamol vs. Ibuprofen in Infancy: The PIPPA Tamariki Trial Finds No Differential Risk for Eczema or Bronchiolitis

Posted by MedXY By MedXY 02/14/2026
The PIPPA Tamariki randomized controlled trial demonstrates that using paracetamol versus ibuprofen as needed in the first year of life does not significantly alter the risk of developing eczema or bronchiolitis by age one, challenging long-standing concerns from observational studies.
Read More
Nirsevimab Halves RSV Bronchiolitis Risk in Infants — High Effectiveness Sustained Despite Emergent RSV‑B Mutations
Posted innews Pediatrics Respiratory

Nirsevimab Halves RSV Bronchiolitis Risk in Infants — High Effectiveness Sustained Despite Emergent RSV‑B Mutations

Posted by MedXY By MedXY 11/11/2025
A multicenter test-negative case-control study in France found high and sustained effectiveness of nirsevimab against RSV bronchiolitis in infants across two consecutive seasons (83.2% and 89.3%), despite emergence of RSV-B mutations.
Read More
  • Evaluating Telehealth Stepped Alcohol Treatment to Reduce Alcohol Use in Chronic Liver Disease: Insights from a 2026 Randomized Controlled Trial
  • Targeting NEK9 to Overcome Immunotherapy Resistance in Hepatocellular Carcinoma by Reprogramming the Tumor Microenvironment
  • BIRC3 Gene Variants Disrupt RIPK1 Signaling, Driving Monogenic Crohn’s Disease: New Insights and Therapeutic Avenues
  • Successful Recanalization Boosts Functional Recovery in Minor Ischemic Stroke: Insights from the TEMPO-2 Trial
  • Distinct Early Cerebral Edema Subtypes as Predictors of Outcome in Cerebral Venous Thrombosis: Insights from the CLOT-VENUS Registry
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prostate cancer public health quality of life randomized clinical trial randomized trial risk stratification semaglutide SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in